JP2013509158A5 - - Google Patents

Download PDF

Info

Publication number
JP2013509158A5
JP2013509158A5 JP2012520621A JP2012520621A JP2013509158A5 JP 2013509158 A5 JP2013509158 A5 JP 2013509158A5 JP 2012520621 A JP2012520621 A JP 2012520621A JP 2012520621 A JP2012520621 A JP 2012520621A JP 2013509158 A5 JP2013509158 A5 JP 2013509158A5
Authority
JP
Japan
Prior art keywords
antibody
fractalkine
binding fragment
seq
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012520621A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013509158A (ja
JP5631991B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2010/069653 external-priority patent/WO2011052799A1/en
Publication of JP2013509158A publication Critical patent/JP2013509158A/ja
Publication of JP2013509158A5 publication Critical patent/JP2013509158A5/ja
Application granted granted Critical
Publication of JP5631991B2 publication Critical patent/JP5631991B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012520621A 2009-10-30 2010-10-28 炎症性疾患を処置するための組成物および方法 Active JP5631991B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25652109P 2009-10-30 2009-10-30
US61/256,521 2009-10-30
PCT/JP2010/069653 WO2011052799A1 (en) 2009-10-30 2010-10-28 Compositions and methods for treating inflammatory disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014189668A Division JP2015027304A (ja) 2009-10-30 2014-09-18 炎症性疾患を処置するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2013509158A JP2013509158A (ja) 2013-03-14
JP2013509158A5 true JP2013509158A5 (https=) 2014-09-25
JP5631991B2 JP5631991B2 (ja) 2014-11-26

Family

ID=43922220

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012520621A Active JP5631991B2 (ja) 2009-10-30 2010-10-28 炎症性疾患を処置するための組成物および方法
JP2014189668A Abandoned JP2015027304A (ja) 2009-10-30 2014-09-18 炎症性疾患を処置するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014189668A Abandoned JP2015027304A (ja) 2009-10-30 2014-09-18 炎症性疾患を処置するための組成物および方法

Country Status (33)

Country Link
US (1) US8932592B2 (https=)
EP (1) EP2493930B1 (https=)
JP (2) JP5631991B2 (https=)
KR (2) KR102099596B1 (https=)
CN (1) CN102597003B (https=)
AR (2) AR078796A1 (https=)
AU (1) AU2010312408B2 (https=)
BR (1) BR112012010266A2 (https=)
CA (1) CA2778895C (https=)
CL (2) CL2012001143A1 (https=)
CY (1) CY1121167T1 (https=)
DK (1) DK2493930T3 (https=)
ES (1) ES2698389T3 (https=)
HR (1) HRP20181973T1 (https=)
HU (1) HUE041952T2 (https=)
IL (1) IL219470A (https=)
JO (1) JO3437B1 (https=)
LT (1) LT2493930T (https=)
MX (1) MX2012005052A (https=)
MY (1) MY158481A (https=)
NZ (1) NZ599779A (https=)
PE (1) PE20121645A1 (https=)
PH (1) PH12012500828A1 (https=)
PL (1) PL2493930T3 (https=)
PT (1) PT2493930T (https=)
RS (1) RS58142B1 (https=)
RU (1) RU2569109C2 (https=)
SI (1) SI2493930T1 (https=)
SM (1) SMT201800637T1 (https=)
TW (1) TWI414308B (https=)
UA (1) UA105073C2 (https=)
WO (1) WO2011052799A1 (https=)
ZA (1) ZA201203002B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9415118B2 (en) * 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
JP6668345B2 (ja) 2014-11-21 2020-03-18 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 修飾された重鎖定常領域を含む抗体
EP3159007A1 (en) 2015-10-19 2017-04-26 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating rheumatoid arthritis
JP2017154975A (ja) * 2016-02-29 2017-09-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
JP2018070473A (ja) * 2016-10-26 2018-05-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 関節リウマチを治療するための医薬組成物
JP2018177701A (ja) * 2017-04-14 2018-11-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 クローン病を治療するための医薬組成物
US20220196674A1 (en) * 2019-04-17 2022-06-23 Abdolamir Landi Treatment of autoimmune liver disease
US20220205980A1 (en) * 2019-04-23 2022-06-30 Eisai R&D Management Co., Ltd. Biomarker for rheumatoid arthritis treatment
KR20220110827A (ko) * 2019-12-09 2022-08-09 알렉시온 파마슈티칼스, 인코포레이티드 시신경척수염 스펙트럼 장애의 치료를 위한 항-c5 항체
CN113087795B (zh) * 2019-12-23 2025-06-10 上海普铭生物科技有限公司 针对趋化因子cx3cl1的抗体及其应用
WO2022092183A1 (ja) 2020-10-30 2022-05-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
CN121537534B (zh) * 2026-01-22 2026-04-07 华中科技大学同济医学院附属协和医院 靶向cx3cl1的嵌合抗原受体-巨噬细胞及在gjb2突变相关遗传性耳聋治疗中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
AU691811B2 (en) * 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6114507A (en) 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
US6096312A (en) 1995-06-30 2000-08-01 Mochida Pharmaceutical Co., Ltd. Agent for suppressing a reduction of CD4+ lymphocytes
CA2225852C (en) * 1995-06-30 2009-04-14 Mochida Pharmaceutical Co., Ltd. Anti-fas ligand antibody and assay method using the anti-fas ligand antibody
US6566503B2 (en) 1996-01-24 2003-05-20 Schering Corporation Mammalian CX3C chemokine
EP0876487B1 (en) 1996-01-24 2008-03-12 Schering Corporation Mammalian cx3c chemokine genes
US6548654B1 (en) 1996-01-24 2003-04-15 Schering Corporation DNA encoding mammalian CX3C chemokine genes
US7115379B1 (en) 1996-01-24 2006-10-03 Schering Corporation Anti-mammalian CX3C cytokine antibodies
US6043086A (en) * 1996-05-07 2000-03-28 Millenium Biotherapeutics, Inc. Neurotactin and uses therefor
EP0966484A4 (en) 1996-05-07 2002-04-17 Millennium Pharm Inc NEUROTACTIN AND APPLICATIONS THEREOF
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
WO2000011950A1 (en) 1998-08-31 2000-03-09 Oregon Health Science University Prevention of cell migration initiation with cmv us28 receptor antagonists
JP2001218581A (ja) 1999-11-30 2001-08-14 Eisai Co Ltd モノクローナル抗体の作製法
US6677321B1 (en) 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
WO2001060406A1 (en) * 2000-02-18 2001-08-23 Millennium Pharmaceuticals, Inc. Therapeutic methods that target fractalkine or cx3cr1
US8647612B2 (en) 2008-03-05 2014-02-11 Encore Health, Llc Dithiol compounds, derivatives, and treatment of presbyopia
JP4263391B2 (ja) * 2001-03-19 2009-05-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗cx3cr1抗体、抗フラクタルカイン抗体及びフラクタルカインの利用
US20020192212A1 (en) * 2001-03-19 2002-12-19 Toshio Imai Uses of anti-CX3CR1 antibody, anti-fractalkine antibody and fractalkine
SE0101082D0 (sv) 2001-03-27 2001-03-27 Astrazeneca Ab Novel use
WO2003018549A2 (en) 2001-08-30 2003-03-06 Chemocentryx, Inc. Bicyclic compounds as inhibitors of chemokine binding to us28
JP2006512313A (ja) 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
PE20050627A1 (es) * 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
EP1520586A1 (en) 2003-09-30 2005-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibition of fractalkine or of its receptor for the treatment of atopic allergic diseases
WO2005032589A1 (ja) * 2003-10-02 2005-04-14 Japan Science And Technology Agency Gvhdの予防及び治療
CA2541533A1 (en) 2003-10-07 2005-04-14 Astrazeneca Ab New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
US8911726B2 (en) 2004-09-22 2014-12-16 Kyowa Hakko Kirin Co., Ltd Stabilized human Igg4 antibodies
ES2641815T3 (es) 2004-10-29 2017-11-14 Eisai R&D Management Co., Ltd. Tratamiento para enfermedades inflamatorias
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
PT2094728E (pt) * 2006-10-26 2013-05-27 Janssen Biotech Inc Métodos de adaptação de anticorpos monoclonais ao ser humano
MX2010002683A (es) * 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.

Similar Documents

Publication Publication Date Title
JP2013509158A5 (https=)
JP6621778B2 (ja) IL7受容体のα鎖に対する抗体‐薬剤候補物質の製造におけるこれらの使用
TWI508745B (zh) TNF-α結合蛋白
JP6681327B2 (ja) 抗pd−1抗体およびその応用
RU2012122203A (ru) Композиции и способы для лечения восполительных нарушений
JP2016512551A5 (https=)
PE20200862A1 (es) Anticuerpos anti-trem2 y metodos relacionados
JP2018183173A5 (https=)
JP2014534242A5 (https=)
JP2015504306A5 (https=)
JP2012501670A5 (https=)
JP2018510636A5 (https=)
JP2009519718A5 (https=)
JP2020511947A5 (https=)
JP2012531922A5 (ja) Toll様受容体2へのヒト化抗体またはその抗原結合部位
RU2008129111A (ru) Антитела к ox40l и способы их применения
JP2018510617A5 (https=)
RU2017137010A (ru) Анти-сеасам6 антитела и их применения
JP2012100667A5 (https=)
JP2018526981A5 (https=)
TW200831533A (en) Interleukin-13 binding proteins
JP2016511277A5 (https=)
JP2016513467A5 (https=)
JP2011514150A5 (https=)
JP2010524435A5 (https=)